Hum. Reprod. Advance Access originally published online on August 31, 2007
Human Reproduction 2007 22(11):2967-2973; doi:10.1093/humrep/dem271
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial
1 Department of Obstetrics and Gynaecology, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark 2 The Medical Research Laboratories, Clinical Institute and Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, DK-8000 Aarhus C, Denmark 3 Institute of Public Health, Department of Epidemiology, University of Aarhus, DK-8000 Aarhus C, Denmark 4 Department of Obstetrics and Gynaecology, Herning Hospital, DK-7400 Herning, Denmark
5 Correspondence address. Tel: +45-8949-6304; Fax: +45-8949-6022; E-mail: ditte.trolle{at}dadlnet.dk
BACKGROUND: Our aim was to assess the effects of metformin on menstrual frequency, fasting plasma glucose (FPG), insulin resistance assessed as HOMA-index, weight, waist/hip ratio, blood pressure (BP), serum lipids, and testosterone levels in women with polycystic ovary syndrome (PCOS)
METHODS: In a randomized, controlled, double-blinded setup, 56 women aged 18–45 with PCOS were treated with either metformin 850 mg or placebo twice daily for 6 months. After a wash-out period of 3 months participants received the alternate treatment for 6 months. The changes in the measured parameters were analysed by intention-to-treat and per protocol
RESULTS: There were no changes in menstrual frequency. In the intention-to-treat analysis, weight and systolic BP were reduced on metformin treatment (p=0.009 and 0.047, respectively), while high-density lipoprotein (HDL) increased (p=0.001). On placebo, weight and FPG increased (p<0.05). Post-hoc subgrouping according to BMI revealed reductions in testosterone (p=0.013), FPG (p=0.018), insulin (p=0.045) and HOMA-index (p=0.022) in obese women. Per protocol analysis showed the following differences between the changes on placebo and metformin (mean (5 - 95 % percentiles): weight (-4.2 (-7.0, -1.9) kg, p<0.001), FPG (-0.23 (-0.44, -0.01) mmol/l, p=0.041), insulin (-4.17 (-8.10, -0.23) mIU/l, p=0.039) and HOMA index (-1.50 (-2.53, -0.47) mIU/l*mmol/l, p=0.006). Weight, FPG and HOMA index were lower after metformin than after placebo. CONCLUSIONS: Metformin treatment lowered weight and systolic blood pressure and increased HDL in women with PCOS. In post-hoc analysis it increased insulin sensitivity and lowered testosterone in obese women. Non-obese women did not benefit from metformin.
Key words: polycystic ovary syndrome/metformin/obesity/randomized controlled trial
Submitted on January 24, 2007; resubmitted on July 4, 2007; accepted on July 19, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. I. Cheang, J. M. Huszar, A. M. Best, S. Sharma, P. A. Essah, and J. E. Nestler Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome Diabetes and Vascular Disease Research, April 1, 2009; 6(2): 110 - 119. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|